Get started
SCYNEXIS, Inc.SCYNEXIS, Inc.SCYNEXIS, Inc.

SCYNEXIS, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

SCYX chart


Full chart

SCYX upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪35.25 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.4640 USD
Net income (FY)
‪−21.29 M‬ USD
Revenue (FY)
‪3.75 M‬ USD
Shares float
‪37.12 M‬
Beta (1Y)
1.56

Employees


Employees (FY)
28
Change (1Y)
−1 −3.45%
Revenue / Employee (1Y)
‪133.79 K‬ USD
Net income / Employee (1Y)
‪−760.29 K‬ USD

About SCYNEXIS, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
David Angulo Gonzalez
Website
scynexis.com
Headquarters
Jersey City
Founded
1999
FIGI
BBG002133YW4
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

SCYX news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as SCYX.

Frequently Asked Questions


The current price of SCYX is 0.9043 USD — it has decreased by −0.91% in the past 24 hours. Watch SCYNEXIS, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange SCYNEXIS, Inc. stocks are traded under the ticker SCYX.
SCYX stock has risen by 6.39% compared to the previous week, the month change is a −16.27% fall, over the last year SCYNEXIS, Inc. has showed a −35.41% decrease.
We've gathered analysts' opinions on SCYNEXIS, Inc. future price: according to them, SCYX price has a max estimate of 7.00 USD and a min estimate of 4.00 USD. Watch SCYX chart and read a more detailed SCYNEXIS, Inc. stock forecast: see what analysts think of SCYNEXIS, Inc. and suggest that you do with its stocks.
SCYX reached its all-time high on Jan 13, 2015 with the price of 150.0000 USD, and its all-time low was 0.7284 USD and was reached on Apr 7, 2025. View more price dynamics on SCYX chart.
See other stocks reaching their highest and lowest prices.
SCYX stock is 9.54% volatile and has beta coefficient of 1.56. Track SCYNEXIS, Inc. stock price on the chart and check out the list of the most volatile stocks — is SCYNEXIS, Inc. there?
Today SCYNEXIS, Inc. has the market capitalization of ‪35.25 M‬, it has increased by 6.39% over the last week.
Yes, you can track SCYNEXIS, Inc. financials in yearly and quarterly reports right on TradingView.
SCYNEXIS, Inc. is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
SCYX earnings for the last quarter are −0.09 USD per share, whereas the estimation was −0.02 USD resulting in a −350.00% surprise. The estimated earnings for the next quarter are −0.19 USD per share. See more details about SCYNEXIS, Inc. earnings.
SCYNEXIS, Inc. revenue for the last quarter amounts to ‪977.00 K‬ USD, despite the estimated figure of ‪10.19 M‬ USD. In the next quarter, revenue is expected to reach ‪137.00 K‬ USD.
SCYX net income for the last quarter is ‪−4.43 M‬ USD, while the quarter before that showed ‪−2.81 M‬ USD of net income which accounts for −57.87% change. Track more SCYNEXIS, Inc. financial stats to get the full picture.
No, SCYX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 19, 2025, the company has 28 employees. See our rating of the largest employees — is SCYNEXIS, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SCYNEXIS, Inc. EBITDA is ‪−37.12 M‬ USD, and current EBITDA margin is −990.84%. See more stats in SCYNEXIS, Inc. financial statements.
Like other stocks, SCYX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SCYNEXIS, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SCYNEXIS, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SCYNEXIS, Inc. stock shows the sell signal. See more of SCYNEXIS, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.